NCT01816035View on ClinicalTrials.gov

Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

April 30, 2017

Conditions
HER2/Neu PositiveRecurrent Breast CarcinomaStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast Cancer
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

BIOLOGICAL

Trastuzumab Emtansine

Given IV

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER

NCT01816035 - Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery | Biotech Hunter | Biotech Hunter